Intermittent Dopaminergic Stimulation causes Behavioral Sensitization in the Addicted Brain and Parkinsonism

作者: Francesco Fornai , Francesca Biagioni , Federica Fulceri , Luigi Murri , Stefano Ruggieri

DOI: 10.1016/S0074-7742(09)88013-6

关键词:

摘要: The gold standard therapy for Parkinson's disease (PD) consists in chronic administration of pulses the dopamine (DA) precursor l -dihydroxyphenylalanine ( -DOPA). Although main brain area which is DA-deficient dorsal striatum (more putamen than caudate nucleus), other DA-innervated regions (i.e., ventral and limbic areas) are affected by systemic -DOPA. While such a produces an increase synaptic nonsynaptic DA, replace neurotransmitter deficiency, peaks extracellular DA course progression produce abnormal involuntary movements related to behavioral sensitization. Methamphetamine (METH), widely abused drug, known sensitization, release as well regions). present review discusses overlapping between these treatments, based on stimulation with emphasis class receptors; signal transduction pathways; rearranged expression neurotransmitters, cotransmitters, their receptors coupled ultrastructural changes. In fact, all levels plasticity show surprising homology following posing mechanisms sensitization during DA-replacement PD very close neurobiological operating METH abuse. line this view growing evidence addictive behaviors patients therapy.

参考文章(164)
K. Fuxe, P. Manger, S. Genedani, L. Agnati, The nigrostriatal DA pathway and Parkinson’s disease Parkinson’s Disease and Related Disorders. ,vol. 70, pp. 71- 83 ,(2006) , 10.1007/978-3-211-45295-0_13
A M Graybiel, J J Canales, Patterns of gene expression and behavior induced by chronic dopamine treatments. Annals of Neurology. ,vol. 47, ,(2000)
Kelly Del Tredici, Udo Rüb, Rob A.I. de Vos, Jürgen R.E. Bohl, Heiko Braak, Where does Parkinson disease pathology begin in the brain Journal of Neuropathology and Experimental Neurology. ,vol. 61, pp. 413- 426 ,(2002) , 10.1093/JNEN/61.5.413
Eva Braak, Daniele Sandmann-Keil, Udo Rüb, Wei Ping Gai, Rob A. I. de Vos, Ernst N. H. Jansen Steur, Kimihito Arai, Heiko Braak, alpha-synuclein immunopositive Parkinson's disease-related inclusion bodies in lower brain stem nuclei. Acta Neuropathologica. ,vol. 101, pp. 195- 201 ,(2001) , 10.1007/S004010000247
Francesco Fornai, Paola Lenzi, Marco Gesi, Paola Soldani, Michela Ferrucci, Gloria Lazzeri, Loredana Capobianco, Giuseppe Battaglia, Antonio De Blasi, Ferdinando Nicoletti, Antonio Paparelli, Methamphetamine produces neuronal inclusions in the nigrostriatal system and in PC12 cells. Journal of Neurochemistry. ,vol. 88, pp. 114- 123 ,(2003) , 10.1046/J.1471-4159.2003.02137.X
Ryuichi Fukui, Per Svenningsson, Toyojiro Matsuishi, Hideho Higashi, Angus C. Nairn, Paul Greengard, Akinori Nishi, Effect of methylphenidate on dopamine/DARPP signalling in adult, but not young, mice. Journal of Neurochemistry. ,vol. 87, pp. 1391- 1401 ,(2003) , 10.1046/J.1471-4159.2003.02101.X
Kazufumi Akiyama, Mitsumoto Sato, Saburo Otsuki, Chiao-chicy Chen, Acute exacerbation of paranoid psychotic state after long-term abstinence in patients with previous methamphetamine psychosis Biological Psychiatry. ,vol. 18, pp. 429- 440 ,(1983)
Jennifer Bearn, Andrew Evans, Michael Kelleher, Kirsten Turner, Andrew Lees, Recognition of a dopamine replacement therapy dependence syndrome in Parkinson's disease: a pilot study☆☆Supplementary Drug and Alcohol Dependence. ,vol. 76, pp. 305- 310 ,(2004) , 10.1016/J.DRUGALCDEP.2004.06.005
Linda P. Dwoskin, Peter A. Crooks, Lihong Teng, Dennis K. Miller, Jeffrey M. Witkin, Patrik Munzar, Jane B. Acri, Steven R. Goldberg, Lobeline Inhibits the Neurochemical and Behavioral Effects of Amphetamine Journal of Pharmacology and Experimental Therapeutics. ,vol. 296, pp. 1023- 1034 ,(2001)